Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo’s ProAir Rival ‘Unlikely To Be Back In 2021’ Following Recall

Q3 2020 Recall Led To $200m Impairment Charge

Executive Summary

Perrigo has moved to allay more serious concerns around its generic ProAir inhaler device, but concedes that it is highly unlikely the lucrative respiratory product will return to the market this year.

You may also be interested in...



Perrigo Rx Divestment Remains ‘On Track’

Perrigo says its deal to divest its Rx business remains “on track,” with the company shunting the prescription unit into “discontinued operations” in the first quarter as it trains its focus on the firm’s future growth engine of consumer self-care.

Sandoz Shakes Up US Albuterol Market With Proventil Deal

Sandoz has struck a US deal to in-license both branded Proventil HFA and an authorized generic version of the albuterol sulfate product from Kindeva Drug Delivery. The deal comes after a busy year for generic versions of albuterol that have transformed the market dynamics for the respiratory treatment.

Perrigo Reaches $1.5bn Deal With Altaris For Rx Business

Perrigo has finally found the right deal to secure the long-awaited divestment of its prescription business, reaching an agreement worth just over $1.5bn with private equity firm Altaris Capital Partners.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel